ARQT News and Press, Arcutis Biotherapeutics Inc. From 02/16/21

NDA submission for topical roflumilast cream as a potential treatment for plaque psoriasis anticipated in the second half of 2021 Positive Phase 3 data on topical roflumilast cream in plaque psoriasis reported in February Advancing topical roflumilast into Phase 3 programs for a...

WESTLAKE VILLAGE, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and cond...

Arcutis Biotherapeutics (ARQT) has priced its public offering of 5.5M common shares at $35.00/share, for expected gross proceeds of $192.5M.Underwriters' over-allotment is an additional 825K shares. Net proceeds will be used to fund the continued development of its multiple programs, for work...

WESTLAKE VILLAGE, Calif,, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and cond...

Bristol Myers Squibb (BMY) is up ~1.6% in premarket after the company announced positive topline results from a pivotal Phase 3 trial evaluating deucravacitinib for the treatment of moderate to severe plaque psoriasis.POETYK PSO-2, the second of two global Phase 3 studies,...

Arcutis Biotherapeutics (ARQT) announces the commencement of an underwritten public offering of $150M of its shares.The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares at the public offering price.Morgan Stanley, Cowen, and Gugg...

WESTLAKE VILLAGE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and cond...

With an outperform rating, the analysts at Cowen raise Arcutis Biotherapeutics ([[ARQT]] +26.0%) to a street-high price target of $80 nearly a threefold value from Friday’s close after the company announced positive trial late-stage trial results for roflumilast cream (ARQ-151) in...

Arcutis Biotherapeutics (ARQT) has surged ~21.9% after the company announced the positive data from two pivotal Phase 3 studies evaluating roflumilast cream (ARQ-151) in plaque psoriasis.The DERMIS-1 and DERMIS-2 trials were identical Phase 3 randomized, parallel, double-blind,...

Roflumilast cream demonstrated statistically significant superiority over vehicle on primary endpoint of IGA Success Favorable safety and tolerability profile in this patient population New Drug Application (NDA) submission anticipated in the second half of 2021 Roflumilast ...